
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …

A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions

